ARTICLE | Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

Attralus looks to obtain clinical POC for first pan-amyloid therapy

September 15, 2020 1:31 AM UTC

Attralus debuted on Monday with a $25 million series A round from venBio Partners, a pan-amyloid imaging agent and a pair of candidates that can be developed for multiple types of systemic ...

Access this Article